Every 424B that Streamex Corp. (STEX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow STEX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STEX filings page.
Streamex Corp. has registered 2,443,750 shares of common stock for resale by Terra Capital Natural Resources Fund Pty Ltd. These shares were issued under a Share Purchase Agreement in exchange for 12,671,297 Empress Royalty Corp. shares, representing a 9.9% Empress stake valued at $12,218,751.
This is a secondary offering, so Streamex will not receive proceeds from any resale; Terra Capital will receive the sale proceeds and pay any selling commissions, while Streamex covers registration expenses. The filing also highlights Streamex’s dual focus on tokenized gold-linked finance and its legacy PURE EP medical device platform, alongside substantial historical losses, going-concern warnings, and extensive regulatory, liquidity, and leverage risks tied to its gold tokenization and prior debt financings.
Streamex Corp is issuing 11,666,667 shares of common stock at $3.00 per share in a primary offering, with underwriters holding a 30-day option for up to 1,750,000 additional shares. Gross proceeds are $35.0 million, with estimated net proceeds of about $32.28 million after fees.
The company plans to use the cash mainly to repay portions of its $50 million secured convertible debentures with Yorkville, which bear 4.00% interest and mature in 2027, and for working capital and general corporate purposes. Shares outstanding are expected to increase from 69,769,461 to 81,436,128, or 83,186,128 if the underwriters’ option is fully exercised, meaning meaningful dilution for new investors buying at a price well above book value.
The filing highlights substantial accumulated losses, going concern warnings, a highly leveraged balance sheet, and significant risks tied to Streamex’s gold-linked tokenization strategy, regulatory uncertainty around digital assets, and reliance on continued access to capital markets.
Streamex Corp is conducting a primary offering of common stock under its shelf registration. The shares will be sold through underwriters, with an additional 30‑day option for more shares, and the company plans to use net proceeds mainly to repay secured convertible debentures and for working capital and general corporate purposes.
The filing highlights Streamex’s shift into gold‑backed tokenization alongside its legacy PURE EP™ medical device platform, while noting substantial historical losses, an accumulated deficit of about $294.1 million as of September 30, 2025, and prior going‑concern warnings. As of January 16, 2026, Streamex reports unaudited cash of $21.5 million, $26.3 million of gold holdings, $10.5 million of marketable securities, and $50.0 million of senior secured convertible debt. The company also discloses an open SEC comment questioning its accounting for the Streamex acquisition and presents illustrative pro forma adjustments showing total assets of approximately $15.5 million and liabilities of approximately $9.9 million if the deal were treated as a reverse recapitalization.